CA58410Q2036
© Newsfile
03.02.2026
MDP
LISTED
TSX
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 12, 2026 to discuss Medexus's results for its third fiscal quarter ended December 31, 2025. Medexus expects to file its financial statements and...
Themefolio
Profiler
Peergroup
© Newsfile
20.11.2025
MDP
LISTED
TSX
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its common shares (TSX: MDP). Under the NCIB, Medexus may purchase for can...
Themefolio
Profiler
Peergroup
© Newsfile
17.11.2025
MDP
LISTED
TSX
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National Bank of Canada as administrative agent. The credit agreement provides for a US$21.0 million term loan facility and a US$5.0 million revolving loan fac...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
13.11.2025
MDP
LISTED
TSX
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
News Preview
Management to host conference call at 8:00 AM Eastern time on Thursday, November 13, 2025Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended Sep...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Newsfile
04.11.2025
MDP
LISTED
TSX
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 13, 2025 to discuss Medexus's results for its second fiscal quarter ended September 30, 2025. Medexus expects to file its financial statements a...
Themefolio
Profiler
Peergroup
© Newsfile
25.09.2025
MDP
LISTED
TSX
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 12, 2025 as directors through the next annual meeting. Sha...
Themefolio
Profiler
Peergroup
© Newsfile
12.08.2025
MDP
LISTED
TSX
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
News Preview
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted EBITDA* of $3.4 million$3.0 million of product-level net revenue from GRAFAPEX in fiscal Q1 2026, relative to $3.0 million of personnel and infrastructure investments, further supporting Medexus's confidence in the product's poten...
Themefolio
Profiler
Peergroup
© Newsfile
26.06.2025
MDP
LISTED
TSX
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
News Preview
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 millionUS commercial launch of GRAFAPEX™ executed in February 2025, following swiftly on the FDA's approval in January 2025, with initial indicators supporting Medexus's confidence in the produc...
Themefolio
Profiler
Peergroup
© Newsfile
17.06.2025
MDP
LISTED
TSX
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 26, 2025 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2025. Medexus expects to file its financial stateme...
Themefolio
Profiler
Peergroup
© Newsfile
17.04.2025
MDP
LISTED
TSX
Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with the provincial government of Quebec for Trecondyv® (treosulfan for injection). The Public Prescription Drug Insurance Plan of the Régie de l'Assurance Maladie du Qué...
Themefolio
Profiler
Peergroup
© Newsfile
07.04.2025
MDP
LISTED
TSX
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update on the progress of the commercial launch of GRAFAPEX™ (treosulfan) for Injection in the United States and announce company management's participation in two upcoming investor conf...
Themefolio
Profiler
Peergroup
© Newsfile
14.03.2025
MDP
LISTED
TSX
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor of Medexus's rights to Gleolan® in the United States, to terminate the license, supply, and distribution agreement between the parties and return r...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
24.02.2025
MDP
LISTED
TSX
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 24, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that GRAFAPEX™ (treosulfan) for Injection is now commercially available in the United States."We are pleased to report this positive development, which marks a strategically important step for...
Themefolio
Profiler
Peergroup
© PR Newswire
06.02.2025
MDP
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - MDP
News Preview
TORONTO, Feb. 6, 2025 /CNW/ - Trading resumes in:
Company: Medexus Pharmaceuticals Inc.
TSX Symbol: MDP
All Issues: Non
Resumption (ET): 10:36:25 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is th...
Themefolio
Profiler
Peergroup
© PR Newswire
06.02.2025
MDP
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - MDP
News Preview
TORONTO, Feb. 6, 2025 /CNW/ - The following issues have been halted by CIRO:
Company: Medexus Pharmaceuticals Inc.
TSX Symbol: MDP
All Issues: No
Reason: Single Stock Circuit Breaker
Halt Time (ET): 10:31:25 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts...
Themefolio
Profiler
Peergroup
© Newsfile
05.02.2025
MDP
LISTED
TSX
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
News Preview
Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: ME...
Themefolio
Profiler
Peergroup
© Newsfile
04.02.2025
MDP
LISTED
TSX
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario Health (Cancer Care Ontario) for Trecondyv® (treosulfan for injection). The Ontario Public Drug Progra...
Themefolio
Profiler
Peergroup
© Newsfile
31.01.2025
MDP
LISTED
TSX
Medexus Schedules Third Fiscal Quarter 2025 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 6, 2025 to discuss Medexus's results for its third fiscal quarter ended December 31, 2024. Medexus expects to file its financial statements and...
Themefolio
Profiler
Peergroup
© Newsfile
31.01.2025
MDP
LISTED
TSX
Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"), is pleased to announce the closing of its previously announced overnight marketed underwritten offering (the "Offering") of 7,500,000 common shares of the Company (the "Common Shares") at a public offe...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2025
MDP
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - MDP
News Preview
TORONTO, Jan. 28, 2025 /CNW/ - Trading resumes in:
Company: Medexus Pharmaceuticals Inc.
TSX Symbol: MDP
All Issues: Yes
Resumption (ET): 10:00 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the n...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2025
MDP
LISTED
TSX
Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares
News Preview
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2025
MDP
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - MDP
News Preview
TORONTO, Jan. 27, 2025 /CNW/ - The following issues have been halted by CIRO:
Company: Medexus Pharmaceuticals Inc.
TSX Symbol: MDP
All Issues: Yes
Reason: Pending News
Halt Time (ET): 03:33 PM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2025
MDP
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - MDP
News Preview
TORONTO, Jan. 22, 2025 /CNW/ - Trading resumes in:
Company: Medexus Pharmaceuticals Inc.
TSX Symbol: MDP
All Issues: Yes
Resumption (ET): 11:30 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the...
Themefolio
Profiler
Peergroup
© Newsfile
22.01.2025
MDP
LISTED
TSX
Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update
News Preview
Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launchToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 22, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update regarding the succe...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2025
MDP
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - MDP
News Preview
TORONTO, Jan. 22, 2025 /CNW/ - The following issues have been halted by CIRO:
Company: Medexus Pharmaceuticals Inc.
TSX Symbol: MDP
All Issues: Yes
Reason: Pending News
Halt Time (ET): 10:01 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to...
Themefolio
Profiler
Peergroup
© Newsfile
15.01.2025
MDP
LISTED
TSX
Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provincial Health Services Authority (PHSA), a publicly funded health service provider in the Canadian province, for a new approved indication for Trecondyv...
Themefolio
Profiler
Peergroup
© Newsfile
02.12.2024
MDP
LISTED
TSX
Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - December 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a fourth amendment to its February 2021 exclusive license agreement with medac relating to commercialization of treosulfan in the United States.Among other thin...
Themefolio
Profiler
Peergroup
© Newsfile
18.11.2024
MDP
LISTED
TSX
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs a...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2024
MDP
LISTED
TSX
Medexus Announces Strong Fiscal Q2 2025 Results
News Preview
Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 millionManagement to host conference call at 8:00 AM Eastern time on Friday, November 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDX...
Themefolio
Profiler
Peergroup
© Newsfile
29.10.2024
MDP
LISTED
TSX
Medexus Schedules Second Fiscal Quarter 2025 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 29, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, November 8, 2024 to discuss Medexus's results for its second fiscal quarter ended September 30, 2024. Medexus expects to file its financial statements and...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2024
MDP
LISTED
TSX
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024 as directors through the next annual meeting. Shar...
Themefolio
Profiler
Peergroup
© Newsfile
16.09.2024
MDP
LISTED
TSX
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has extended the review period for the New Drug Application for treosulfan by three month...
Themefolio
Profiler
Peergroup
© Newsfile
07.08.2024
MDP
LISTED
TSX
Medexus Announces Strong Fiscal Q1 2025 Results
News Preview
Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, August 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)...
Themefolio
Profiler
Peergroup
© Newsfile
30.07.2024
MDP
LISTED
TSX
Medexus Schedules First Fiscal Quarter 2025 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 8, 2024 to discuss Medexus's results for its first fiscal quarter ended June 30, 2024. Medexus expects to file its financial statements and MD&A...
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2024
MDP
LISTED
TSX
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024
News Preview
FDA has Accepted for Review the Treosulfan NDAManagement to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the co...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2024
MDP
LISTED
TSX
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2024. Medexus expects to file its financial statem...
Themefolio
Profiler
Peergroup
© Newsfile
06.06.2024
MDP
LISTED
TSX
FDA Accepts for Review Treosulfan NDA Resubmission
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for review medac's April 2024 resubmission of the New Drug A...
Themefolio
Profiler
Peergroup
© Newsfile
01.05.2024
MDP
LISTED
TSX
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's commercialization rights to Metoject®, have elect...
Themefolio
Profiler
Peergroup
© Newsfile
02.04.2024
MDP
LISTED
TSX
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024.Event: 2024 Bloom Burton & Co. Healthcare Investor Conferenc...
Themefolio
Profiler
Peergroup
© Newsfile
26.03.2024
MDP
LISTED
TSX
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
News Preview
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration...
Themefolio
Profiler
Peergroup
© Newsfile
07.02.2024
MDP
LISTED
TSX
Medexus Announces Fiscal Q3 2024 Results
News Preview
Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its ope...
Themefolio
Profiler
Peergroup
© Newsfile
30.01.2024
MDP
LISTED
TSX
Medexus Schedules Third Fiscal Quarter 2024 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 8, 2024 to discuss Medexus's results for its third fiscal quarter ended December 31, 2023. Medexus expects to file its financial statements and...
Themefolio
Profiler
Peergroup
© Newsfile
08.01.2024
MDP
LISTED
TSX
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
News Preview
Topical terbinafine has been widely used in other markets to treat fungal nail infectionsIf and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million on an annual basis*Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 8, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) tod...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2023
MDP
LISTED
TSX
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
News Preview
Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performanceManagement to host conference call at 8:00 AM Eastern time on Thursday, November 9, 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 8, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MED...
Themefolio
Profiler
Peergroup
© Newsfile
01.11.2023
MDP
LISTED
TSX
Medexus Schedules Second Fiscal Quarter 2024 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 9, 2023 to discuss Medexus's results for its second fiscal quarter ended September 30, 2023. Medexus expects to file its financial statements an...
Themefolio
Profiler
Peergroup
© Newsfile
17.10.2023
MDP
LISTED
TSX
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that, in connection with its recently completed bought-deal public offering (Offering) of units (Units), Medexus has issued an additional 508,484 Units at a price of C$2.95 per Unit for an additional...
Themefolio
Profiler
Peergroup
© Newsfile
16.10.2023
MDP
LISTED
TSX
Medexus Fully Repays Convertible Debentures In Cash At Maturity
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 16, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has made in cash the final maturity date payment of C$51.1 million (or approximately US$37.5 million) to Computershare Trust Company of Canada as trustee for holders of Medexus's 6% unsecured convertible debentures due Oct...
Themefolio
Profiler
Peergroup
© Newsfile
06.10.2023
MDP
LISTED
TSX
Medexus Announces Closing of C$10 Million Bought-Deal Public Offering
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 6, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the closing of its bought-deal public offering of 3,389,900 units (Units) at a price of C$2.95 per Unit for aggregate gross proceeds to Medexus of C$10,000,205 (Offering). The net proceeds from the Of...
Themefolio
Profiler
Peergroup
© Newsfile
29.09.2023
MDP
LISTED
TSX
Medexus and medac Agree to Amend US Treosulfan Agreement
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a third amendment to its February 2021 exclusive license agreement with medac GmbH relating to commercialization of treosulfan in the United States.Among othe...
Themefolio
Profiler
Peergroup
© Newsfile
21.09.2023
MDP
LISTED
TSX
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
News Preview
All director nominees reelected and all other company proposals approved by shareholdersToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management info...
Themefolio
Profiler
Peergroup
© Newsfile
05.09.2023
MDP
LISTED
TSX
Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility
News Preview
Medexus expects net proceeds, together with projected cash on hand, to fully satisfy convertible debentures in cash at maturity in October 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 5, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into an amendment to the company's senior secured credit agreeme...
Themefolio
Profiler
Peergroup
© Newsfile
17.08.2023
MDP
LISTED
TSX
Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B
News Preview
Poster presentation at National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 highlights effective prophylaxis, control of bleeding episodes, and consistent safety profilePhase 3/4 data presentation follows FDA acceptance for review of IXINITY® supplemental Biological License Application for pediatric patientsToronto, Ontario...
Themefolio
Profiler
Peergroup
© Newsfile
09.08.2023
MDP
LISTED
TSX
Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million
News Preview
Fiscal Q1 2024 revenue reflects a 37% increase over fiscal Q1 2023, demonstrating strong revenue growth and continued overall performanceManagement to host conference call at 8:00 AM Eastern time on Thursday, August 10, 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)...
Themefolio
Profiler
Peergroup
© Newsfile
04.08.2023
MDP
LISTED
TSX
Medexus to Participate in Fireside Chat at SHARE Series Event
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 4, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will present at the SHARE Series event on Monday, August 14, 2023 at 8:30 AM Eastern time.Event: SHARE SeriesDate: August 14, 2023Location: Virtual PresentationMedexus Presentat...
Themefolio
Profiler
Peergroup
© Newsfile
02.08.2023
MDP
LISTED
TSX
Medexus Schedules First Fiscal Quarter 2024 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 2, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 10, 2023 to discuss Medexus's results for its first fiscal quarter ended June 30, 2023. Medexus expects to file its financial statements and MD&...
Themefolio
Profiler
Peergroup
© Newsfile
12.07.2023
MDP
LISTED
TSX
Medexus Announces Preliminary Revenue for Fiscal Q1 2024
News Preview
Preliminary estimates indicate revenue is expected to exceed US$31 million for fiscal quarter ended June 30, 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 12, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company's fiscal quarter ended June 30, 2023 (the c...
Themefolio
Profiler
Peergroup
© Newsfile
21.06.2023
MDP
LISTED
TSX
Medexus Generates Record Revenue of Us$108.1 Million in Fiscal Year 2023
News Preview
Management to Host Conference Call at 8:00 Am Eastern Time on Thursday, June 22, 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year e...
Themefolio
Profiler
Peergroup
© Newsfile
15.06.2023
MDP
LISTED
TSX
FDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric Patients
News Preview
Expanded indication would cover patients 12 years of age or younger, a population that comprises approximately one in three patients treated for hemophilia B in the United StatesToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 15, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Admin...
Themefolio
Profiler
Peergroup
© Newsfile
14.06.2023
MDP
LISTED
TSX
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference Call
News Preview
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 14, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 22, 2023 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2023. Medexus expects to file its financial stateme...
Themefolio
Profiler
Peergroup
© Newsfile
13.06.2023
MDP
LISTED
TSX
Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023
News Preview
Princess Margaret Cancer Center's retrospective analysis found a 30% improvement (83.2% vs 53.2%) in one-year overall survival for patients treated with treosulfan, among other positive findingsToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 13, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to highlight positiv...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
